Microchip Biotech (688321.SH) announced semi-annual results, with net profit of 71.3806 million yuan to mother, an increase of 141.21% over the previous year

According to Zhitong Finance App News, Microchip Biotech (688321.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved operating income of 543 million yuan, an increase of 33.60%; net profit attributable to shareholders of listed companies was 71.3806 million yuan, an increase of 141.21% year on year; net profit after deducting non-recurring profit and loss was 64.7018 million yuan, an increase of 218.41% year on year; basic earnings per share were 0.1,645 yuan.

During the reporting period, the company's product siglitazide maintained more than double growth compared to the first half of last year, and two solid preparation production lines in its eight workshops obtained drug GMP compliance inspection notices in the second quarter, providing strong support for production capacity in the second half of the year.